- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-393/23 R: Order of the President of the General Court of 1 September 2023– Teva v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Lack of urgency)
ECLI:EU:UNKNOWN:62023TB0393
62023TB0393
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
Series C
C/2023/341
30.10.2023
(Case T-393/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Lack of urgency)
(C/2023/341)
Language of the case: English
Parties
Applicant: Teva GmbH (Ulm, Germany) (represented by: Z. West and G. Morgan, Solicitors, and by S. Love, Barrister)
Defendant: European Commission (represented by: E. Mathieu and A. Spina, acting as Agents)
Re:
By its application based on Articles 278 and 279 TFEU, the applicant seeks, in essence, suspension of operation of Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending Commission Implementing Decision C(2014) 601 final of 30 January 2014 granting marketing authorisation (‘MA’) for the medicinal product for human use Tecfidera — Dimethyl fumarate (‘Tecfidera’) under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended (‘the contested decision’), and any subsequent decision or act extending or replacing the contested decision in so far as they concern the applicant.
Operative part of the order
1.The application for interim measures is dismissed.
2.There is no longer any need to rule on the application to intervene submitted by Biogen Netherlands BV.
3.The costs relating to the proceedings for interim relief are reserved.
4.Each party shall bear its own costs relating to the application to intervene submitted by Biogen Netherlands.
ELI: http://data.europa.eu/eli/C/2023/341/oj
ISSN 1977-091X (electronic edition)
* * *
Language of the case: English.